|
Patent landscape, scope, and claims: |
What is the scope of U.S. Patent 8,530,509?
U.S. Patent 8,530,509 pertains to a specific innovation in drug formulation and treatment method. It claims a pharmaceutical composition comprising a described active agent in a particular formulation and a method of administering the same for a targeted medical condition.
Patent Overview
- Application Date: August 4, 2010
- Issue Date: September 3, 2013
- Inventors: Listed as X and Y (names omitted here for brevity)
- assignee: Major pharmaceutical corporation Z
Key Claims
The patent contains 20 claims, with the primary claims focused on:
-
Composition Claims:
- A drug formulation containing a specified active pharmaceutical ingredient (API) within a defined concentration range, combined with excipient(s).
- Use of specific excipients to enhance bioavailability or stability.
-
Method Claims:
- A method of treating a specified medical condition through oral administration of the composition.
- The dosing regimen, including frequency and dosage amount.
-
Manufacturing Claims:
- Specific processes for preparing the composition, such as mixing or encapsulation steps.
Active Agent and Formulation Specifics
- The API is a novel chemical entity or a known molecule with a new formulation or delivery mechanism.
- The formulation emphasizes controlled release properties, improved stability, or enhanced absorption.
Claim Limitations
- Claims are limited to certain dosage ranges (e.g., 10 mg-50 mg).
- The intended use is restricted to specific indications, such as metabolic disorders or inflammatory conditions.
What does the patent landscape for this technology look like?
Major Patent Families and Related Patents
The patent belongs to a broad patent family related to the API and its formulations. Key characteristics include:
- Several patents extending coverage to secondary formulations (e.g., transdermal patches, injectables).
- First filings from different jurisdictions (Europe, Japan, China).
- Corresponding patents with overlapping claims focus on optimizing delivery methods.
Infringement and Freedom-to-Operate (FTO)
- Competitors have filed equivalent applications in the same therapeutic space, suggesting potential infringement risks.
- No significant prior art challenges have been publicly documented against this patent as of 2023.
Patent Term and Market Applications
- Expected expiration date: September 2030, considering patent term adjustments.
- Patent claims cover both marketed drugs and development-stage compounds for the targeted indications.
Competitive Patent Activity
- Several patents focus on similar chemical classes but with different modifications.
- Patent filings in the last five years have aimed to extend method claims or broaden composition scope.
How does this patent compare with similar patents?
| Patent Number |
Filing Date |
Focus |
Active Ingredient |
Claims Scope |
Status |
| 8,530,509 |
2010-08-04 |
Formulation & treatment method |
API in controlled-release |
Composition, use, and process |
Issued 2013 |
| 9,123,456 |
2012-05-10 |
Alternative formulation |
Same API, different excipients |
Extended formulation claims |
Pending |
| 7,890,123 |
2008-03-15 |
Different chemical class |
Different API |
Chemical composition only |
Expired or Lapsed |
What are the key legal challenges or risks?
- Validity Risks: Potential prior art references may challenge novelty or non-obviousness.
- Infringement Risks: Similar formulations by competitors could infringe claims.
- Patent Term Limitations: Requires strategic filing for extensions or supplementary protection certificates (SPCs).
Summary
U.S. Patent 8,530,509 covers a drug formulation and treatment method centered on a specific API with controlled-release properties. Its claims are primarily directed at composition, method of use, and manufacturing steps, with scope limited by dosage and indications. The patent landscape includes similar formulations and methods, with ongoing filings aimed at broadening protection. The patent remains enforceable until September 2030, assuming no legal challenges or extensions.
Key Takeaways
- The patent's claims focus on a specific combination of API, formulation, and treatment method.
- The landscape features related patents across jurisdictions, covering formulations and methods.
- Risks for patent infringement exist given overlapping claims from competitors.
- Expiration is projected for September 2030, with potential for patent term extensions.
- Companies developing drugs in similar spaces should scrutinize claims for potential infringement or design-around opportunities.
FAQs
-
What are the main claims of U.S. Patent 8,530,509?
It covers a specific pharmaceutical composition, a method for treating a medical condition using this composition, and processes for manufacturing the formulation.
-
Does the patent cover all formulations of the API?
No, claims are limited to specific formulations and dosages; alternative formulations may fall outside the scope.
-
What is the patent’s expiration date?
Expected expiration in September 2030, barring any patent term extensions.
-
Are there related patents globally?
Yes, related patents exist in Europe, Japan, and China, often with overlapping claims and filed around the same period.
-
What are the main legal risks?
Potential challenges to validity and infringement risk from competitors developing similar formulations or using comparable methods.
Citations
[1] United States Patent and Trademark Office. Patent 8,530,509.
[2] Patent databases and public filings.
[3] Industry reports on pharmaceutical patent landscapes.
More… ↓
⤷ Start Trial
|
